We serve Chemical Name:2-Chlor-N-isopropyl-2′,3′-dimethylacetanilid CAS:6291-28-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Chlor-N-isopropyl-2′,3′-dimethylacetanilid
CAS.NO:6291-28-7
Synonyms:N-Isopropyl-2-chlorbenzamid;2-Chloro-2′,6′-dimethyl-N-isobutoxymethylacetanilide;3-chlorobenzoic acid isopropylamide;2-chloro-N-isopropylbenzamide;2-chloro-N-isopropyl-2′,3′-dimethylacetanilide;2′,6′-dimethyl-N-isobutoxymethyl-2-chloroacetanilide;2-Chlor-N-isopropylbenzamid;DELACHLOR;N-chloroacetyl-N-isopropyl-2,3-dimethylaniline;2-chloro-N-isobutoxymethyl-2′,6′-dimethylacetanilide;o-Chlor-benzoylisobutylamid
Molecular Formula:C10H12ClNO
Molecular Weight:197.66100
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:316.2ºC at 760 mmHg
Density:1.128g/cm3
Index of Refraction:1.528
PSA:29.10000
Exact Mass:197.06100
LogP:2.86910
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-Isopropyl-2-chlorbenzamid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,o-Chlor-benzoylisobutylamid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,DELACHLOR Use and application,o-Chlor-benzoylisobutylamid technical grade,usp/ep/jp grade.
Related News: SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. nitrogen dioxide manufacturers It has also been possible to prepare enzymes that can function effectively in organic solvents, thereby dramatically increasing the number of reactions possible. Dregeoside Ga1 suppliers The FDA in announcing its approval noted that four, 12-week placebo-controlled clinical studies that included a total of 1,143 participants showed Nourianz offered a statistically significant decrease from baseline in daily “off” time compared to those on placebo. 4,5-Bis(methylthio)-1,3-dithiole-2-thione vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. nitrogen dioxide manufacturers It has also been possible to prepare enzymes that can function effectively in organic solvents, thereby dramatically increasing the number of reactions possible. Dregeoside Ga1 suppliers The FDA in announcing its approval noted that four, 12-week placebo-controlled clinical studies that included a total of 1,143 participants showed Nourianz offered a statistically significant decrease from baseline in daily “off” time compared to those on placebo. 4,5-Bis(methylthio)-1,3-dithiole-2-thione vendor & factory.
